Policy Statements
The American Society of Hematology represents the interests of hematologists and their patients before Congress and the Executive branch, advocating for the best science and practice of hematology. When warranted, ASH issues policy statements on research, practice, training, or quality of care issues that are likely to have an impact on the field.
Statement on a Strong Blood Supply
The American Society of Hematology (ASH) represents over 18,000 physicians, scientists, and medical trainees committed to the study of blood and treatment of blood-related diseases. ASH members include clinicians who specialize in treating children a...
Read moreMaternal Rights Policy Statement
Maternal deaths have been increasing in the United States since 2000. According to the Centers for Disease Control and Prevention (CDC), the maternal mortality rate was 20.1 per 100,000 live births in the United States in 2019. The corresponding num...
Read moreStatement in Support of the Value of Scholarly Publishers
As a member of the Council of Medical Specialty Societies (CMSS) and an organization committed to promoting and supporting clinical and scientific research in hematology, the American Society of Hematology (ASH) supports the CMSS statement on the val...
Read moreASH Statement Addressing Diversity, Equity, and Inclusion in Hematology Research, Practice, and Training
The American Society of Hematology is committed to addressing and reversing historic inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and elevating diverse voices across our patient and hea...
Read moreASH Position on Sickle Cell Trait
ASH Position It is medically inaccurate to claim sickle cell crisis as the cause of death based solely on the presence of sickled cells at autopsy. Sudden death is an extraordinarily rare occurrence in sickle cell trait and the finding of sickle cell...
Read moreAccess to Hematology Care in an Age of Innovation
The American Society of Hematology (ASH) believes that all individuals should have access to and be able to afford high-quality, clinically appropriate care, including innovative therapeutics. Hematologists treat patients with malignant hematologic d...
Read moreASH Statement in Support of Palliative Blood Transfusions in Hospice Setting
The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. As an organization of physicians and scientists who care f...
Read moreStatement on Opioid Use in Patients with Hematologic Diseases and Disorders
The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study of blood and treatment of blood-related diseases. ASH members include clinicians who specialize in treating c...
Read moreASH Policy Statement in Support of Patient Access to Safe and Effective Drugs
ASH Policy Statement in Support of Patient Access to Safe and Effective DrugsAs an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, as well as...
Read moreStatement on Screening for Sickle Cell Trait and Athletic Participation
Background The American Society of Hematology (ASH) represents approximately 16,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. ASH members include clinicians who specialize i...
Read more- 1
- 2